About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.



  • Dec.JVM launches new pharmaceutical packaging machine that can speed up the automatic dispensing procedure and save wrapping paper
  • LAPSCOVERY applied new bio drug Rolontis submitted for US FDA approval
  • Nov.Europe’s No.1 Pharmacy chain adopts JVM ‘s automatic pharmaceutical packaging machine
  • Hanmi conducts full-scale anti-smoking campaign at all its workplaces
  • Oct.Hanmi presents clinical trial results of the treatments applied with LAPSCOVERY technology at EASD
  • Athenex gets FDA nod for testing oral breast cancer treatment, Eribulin
  • Hanmi receives FDA orphan drug designation for HM43239 in treatment of AML
  • Sep.Spectrum unveils the latest interim results of the phase 2 clinical trial on ‘poziotinib’ at WCLC
  • Aug.Monterizine Capsule phase 3 clinical test results featured in the Journal of Clinical Therapeutics
  • July.Releases phase 3 clinical result of Rolontis in an oral presentation at the MASCC
  • Slated to market and sell Hugel’s Gugu-fill(Hyaluronic Acid Filler)
  • Jun.Presents three next-generation anti-cancer drugs at ASCO
  • Releases clinical results of Amosartan/Rovelito at ESH
  • Launches Monterizine Chewable Tab for children
  • May.Wins FDA nod for arthritis treatment ‘Hyalrheuma’
  • Sanofi begins phase 3 trials of Hanmi’s diabetes drug candidate ‘efpeglenatide’
  • Apr. Janssen starts phase 2 study on HM12525A, a biologic drug for the treatment of diabetes and obesity developed by Hanmi
  • Unveils three new anti-cancer drug candidates at AACR
  • Spectrum presents clinical trial results of poziotinib at AACR
  • Wins FDA approval of LAPSTriple Agonist phase 1 clinical trial
  • Oraxol gets orphan drug designation for angiosarcoma
  • JVM, an affliliate of Hanmi awarded for excellence in corporate disclosure
  • Spectrum publishes the trial results for poziotinib, a non-small-cell lung cancer treatment on Nature Medicine
  • Mar. Hanmi Tams 0.4mg phase 3 clinical test results featured in the Journal of Clinical Therapeutics
  • Selected the short track speed skating gold medalist Kim Alang as its new model for Tenten, a chewable nutritional supplement
  • Feb.LAPSGlucagon Analog receives FDA Breakthrough Therapy Designation in congenital hyperinsulinemia
  • Spectrum presents ‘Rolontis’ met the Primary Endpoint in the Phase 3 ADVANCE study… sets to file BLA within 4Q
  • Sanofi sets to start two phase 3 clinical trials of efpeglenatide in 2018
  • Received industry first ‘BPW Gold Award’ for promoting gender equality
  • Jan.Promotes innovative drugs for NASH, rare diseases and targeted anti-cancer at JP Morgan event
  • Reports 916.6 billion won in revenue in 2017, operating profit soars 212.3%